Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

151 to 175 of 261 results

Prostate cancer drug market will more than double to $9.1 billion in 2021

06-11-2012

The prostate cancer drug market will more than double, increasing from $4.1 billion in 2011 to $9.1 billion…

Astellas PharmaGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalXtandiZytiga

FDA expands Bayer/Janssen's Xarelto use to treat, reduce recurrence of blood clots

05-11-2012

The US Food and Drug Administration (FDA) late Friday approved German drug major Bayer's (BAYN: DE) oral…

BayerBiotechnologyCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C

02-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit has entered into a…

Anti-viralsBiotechnologyGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirVertexVX-135

Study finds potential use of ustekinumab for Crohn's disease

18-10-2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

Johnson & Johnson beats expectations, despite 7% 3rd-qtr profit fall

17-10-2012

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday revealed that its third-quarter 2012 profit…

FinancialJohnson & JohnsonPharmaceutical

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16-10-2012

The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Reimbursement barriers a factor that strongly constrains Zytiga prescribing in USA

14-10-2012

In a little more than a year after its launch, a sizeable proportion of surveyed US oncologists indicate…

Astellas PharmaJanssenJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalPricingXtandiZytiga

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA

02-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

ESMO 2012 Congress highlights

01-10-2012

The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

Red tape delaying access to new TB drug in South Africa

20-09-2012

South Africa's drug regulatory authority is placing unreasonable hurdles in the way of desperately ill…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonPharmaceuticalRegulationRest of the World

Janssen files BLA for IV form of Simponi for moderate-to-severe RA

20-09-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech has submitted a Biologics…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSimponi Injection

Johnson & Johnson to set up innovation centers to accelerate partnering

19-09-2012

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday said it plans to establish four regional…

Johnson & JohnsonLicensingMergers & AcquisitionsPharmaceuticalResearch

Senior appointments at Teva and Johnson & Johnson

14-09-2012

Israel's Teva Pharmaceutical Industries (NYSE: TEVA) has announced the appointment of Itzhak Krinsky…

GenericsJohnson & JohnsonManagementPharmaceuticalTeva Pharmaceutical Industries

Janssen responds to FDA's Xarelto CRL; resubmits sNDA

10-09-2012

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, German drug major Bayer's (BAYN:…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

ImmuNext partners with Janssen in up to $150 million cancer discover deal

06-09-2012

Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health…

ImmuNextJanssen BiotechJohnson & JohnsonLicensingOncologyPharmaceuticalResearch

Janssen-Cilag files for EU approval of bedaquiline in MDR-TB

02-09-2012

Johnson & Johnson (NYSE: JNJ) Belgium-based subsidiary Janssen-Cilag International submitted a Marketing…

Antibiotics and Infectious diseasesbedaquilinedelamanidEuropeJanssen-CilagJohnson & JohnsonOtsukaPharmaceuticalRegulation

Genmab leaps on $1.1 billion daratumumab deal with Janssen

31-08-2012

Denmark's Genmab A/S (OMX: GEN) saw its shares leap 20% to 81 Danish kroner in morning trading yesterday,…

BiotechnologydaratumumabFinancialGenmabHuMax-CD38JanssenJohnson & JohnsonLicensingOncologyPharmaceutical

Janssen to pay $181 million in Risperdal settlement

31-08-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals yesterday announced a settlement…

JanssenJohnson & JohnsonLegalMarkets & MarketingNorth AmericaPharmaceuticalRisperdal

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA

30-08-2012

There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries…

BiotechnologyJanssenJohnson & JohnsonNeurologicalNorth AmericaNucyntaOncologyPharmaceuticalRegulationZytiga

First-line multiple myeloma patient share in Europe is variable by country

29-08-2012

Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

US surveyed PCPs and pain specialists experienced reimbursement restrictions for Janssen's Nucynta ER

28-08-2012

The majority of US surveyed primary care physicians (PCPs) and pain specialists indicate that they have…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaNucyntaPfizerPharmaceuticalPricingtanezumab

151 to 175 of 261 results

Back to top